ANTIBODY-MEDIATED REJECTION

Clinical trials for ANTIBODY-MEDIATED REJECTION explained in plain language.

Never miss a new study

Get alerted when new ANTIBODY-MEDIATED REJECTION trials appear

Sign up with your email to follow new studies for ANTIBODY-MEDIATED REJECTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 3 Not yet recruiting 1 Not yet finished but already full! 2 Completed 1

Four-Year Follow-Up for kidney rejection drug shows promise

Disease control Not yet recruiting

This study continues monitoring a drug called felzartamab in kidney transplant patients whose bodies are attacking their new kidneys. It follows 120 people from an earlier trial for up to four more years to check long-term safety and effects. Researchers will track kidney health …

Matched conditions: ANTIBODY-MEDIATED REJECTION

Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control

Last updated Mar 13, 2026 15:06 UTC

ANTIBODY-MEDIATED REJECTION

Get alerted when new ANTIBODY-MEDIATED REJECTION trials appear

Four-Year Follow-Up for kidney rejection drug shows promise